Effectiveness and Safety of GyroGlove in Stabilising Hand Tremors in Essential Tremor
Effectiveness and Safety of GyroGlove in Stabilising Hand Tremors in Essential Tremor
This is a multi-centre, single-blind, placebo-controlled trial with an open label follow up. After the baseline assessment, all participants will receive the GyroGlove for two weeks during the open label follow up part of the trial. All gloves will be retrieved and returned to GyroGear after closure of the study.
All participants will attend 2 in-clinic assessment sessions (Baseline (day 0), Follow-up (day 14)) after screening visit. The baseline session will last approximately 120 minutes whilst the 2-week assessment will last approximately 60-80 minutes. At baseline assessment, participants will perform protocol-specific activities with both investigational devices (i.e. GyroGlove and Placebo).
In addition to in-clinic assessments, participants will complete self-assessments at Day -3 prior baseline visit (i.e. Day 0,) and at Day 5 and 10 from baseline (i.e. Day 0), when they started using GyroGlove at home.
All participants will be blinded at the baseline (Day 0), as assessments will be performed with GyroGlove and a placebo device in a pre-defined sequence. Each participant will act as the control for him/herself and will be blinded to the interventions order.
The sequence of interventions in the study has been pre-defined, owing to the potential for longitudinal effects of wearing the device interfering with the accurate study outcome measurement.
Inclusion Criteria:
And
Exclusion Criteria:
Other possible causes of tremor, including Parkinson's disease, drug-induced, enhanced physiological tremor
Presence of tremor around the elbow and shoulder limiting participants to perform required test/procedure in the study
Has implanted electrical medical device, e.g., pacemaker, defibrillator, or deep brain stimulator
Clinically diagnosed alcohol use disorder or illicit substance use (exception medical cannabis)
Change in medication for tremor within 1 month prior to study enrolment
Change in antidepressant medication within 3 months prior to study enrolment
Has received botulinum toxin injection for hand tremor within 4 months prior to study enrolment
Has been diagnosed with any of the following conditions affecting the hand and/or arm:
Previous thalamotomy procedure, including stereotactic thalamotomy, gamma knife radio surgical thalamotomy, and focused ultrasound for the treatment of tremor.
Neurological conditions aside from essential tremor that may affect the conduct of the study
Peripheral neuropathy affecting the upper extremity
Are participating or have participated in any interventional clinical trial or study in the last 30 days which may confound the results of this study, unless approved by the Sponsor
Inability to follow simple instructions
Pregnancy
clinical@gyrogear.co+44 2045773038
Farmington Hills, Michigan 48334, United States
peter@questri.com248-957-8940
Cambridge, England CB2 0QQ, United Kingdom
wondo@houstonmethodist.org346-238-9068
James.Boyd@uvmhealth.org802-847-4589
paul.worth@addenbrookes.nhs.uk01223349289
nicola.pavese@newcastle.ac.uk0191 2081264
Nagaraja.Sarangmat@ouh.nhs.uk07912145463
Richard.Walker@northumbria-healthcare.nhs.uk07795617590